Quimioterapia adyuvante en cáncer epitelial de ovario en estadios avanzados / Adjuvant chemotherapy in advanced stage epithelial ovarian cancer

Objetivo: describir la experiencia en el manejo de quimioterapia adyuvante en pacientes con cáncer epitelial avanzado de ovario en el Hospital de San José, Bogotá, Colombia, entre 2016 y 2020. Materiales y métodos: estudio de cohorte histórica descriptiva de pacientes con diagnóstico de cáncer epitelial del ovario, citorreducción quirúrgica completa y que recibieron 6 ciclos de quimioterapia con carboplatino-paclitaxel. El tiempo del seguimiento fue aproximadamente 1 año. Resultados: de 45 pacientes estudiadas con citorreducción óptima el cáncer progresó después de la quimioterapia adyuvante en 13/45 casos (29%), presentó respuesta parcial en 2/45 casos (4%) y completa en 30/45 (66.6). En estadio quirúrgico avanzado (estadios III y IV FIGO 2014) la neoplasia progresó en 12/36 pacientes (33.3%), hubo respuesta parcial en 2/36 (5.6%) y completa en 22/36 (61%). Los efectos adversos al tratamiento de quimioterapia fueron (n = 45/45, 100%), alopecia (n = 45/45, 100%), náuseas y vómito (n = 30/45, 67%), artralgias (n = 10/45, 22%), neuropatías periféricas reportada como parestesias en manos y pies (n = 6/45, 13%) y un caso (2%) de toxicidad hematológica grado I (neutropenia leve). Conclusiones: 66,6% de las pacientes con cáncer epitelial de ovario manejadas con citorreducción óptima y quimioterapia adyuvante tuvieron respuesta completa a la quimioterapia, con mejor tolerancia a los efectos adversos de la quimioterapia (carboplatino-paclitaxel).

Objective: to describe the efficacy of adjuvant chemotherapy in patients with advanced epithelial ovarian cancer in Hospital de San José, Bogotá, Colombia, between 2016 and 2020. Materials and methods: a descriptive historical cohort study in patients with epithelial ovarian cancer managed with complete surgical cytoreduction followed by 6 carboplatin-paclitaxel chemotherapy cycles. The follow-up time was approximately 1 year. Results: out of the 45 studied patients managed with optimal cytoreduction followed by adjuvant chemotherapy, cancer progression was observed in 13/45 (29%) cases, 2/45 (4%) showed partial response and 30/45 (66.6%) showed complete response. Chemotherapy-related adverse effects occurred in (n = 45/45, 100%), including alopecia (n = 45/45, 100%), nausea and vomiting (n = 30/45, 67%), arthralgia (n = 10/45, 22%), peripheral neuropathy reported as hands and feet paresthesia (n = 6/45, 13%) and one case (2%) had grade I hematologic toxicity (mild neutropenia). Conclusions: 66.6% of patients with epithelial ovarian cancer treated with optimal cytoreduction and adjuvant chemotherapy exhibited complete response to chemotherapy with better tolerance to chemotherapy (carboplatin-paclitaxel) related adverse effects.

Structural and functional connectivity of the ascending arousal network for prediction of outcome in patients with acute disorders of consciousness.

To determine the role of early acquisition of blood oxygen level-dependent (BOLD) signals and diffusion tensor imaging (DTI) for analysis of the connectivity of the ascending arousal network (AAN) in predicting neurological outcomes after acute traumatic brain injury (TBI), cardiopulmonary arrest (CPA), or stroke. A prospective analysis of 50 comatose patients was performed during their ICU stay. Image processing was conducted to assess structural and functional connectivity of the AAN. Outcomes were evaluated after 3 and 6 months. Nineteen patients (38%) had stroke, 18 (36%) CPA, and 13 (26%) TBI. Twenty-three patients were comatose (44%), 11 were in a minimally conscious state (20%), and 16 had unresponsive wakefulness syndrome (32%). Univariate analysis demonstrated that measurements of diffusivity, functional connectivity, and numbers of fibers in the gray matter, white matter, whole brain, midbrain reticular formation, and pontis oralis nucleus may serve as predictive biomarkers of outcome depending on the diagnosis. Multivariate analysis demonstrated a correlation of the predicted value and the real outcome for each separate diagnosis and for all the etiologies together. Findings suggest that the above imaging biomarkers may have a predictive role for the outcome of comatose patients after acute TBI, CPA, or stroke.

Establishing an acquisition and processing protocol for resting state networks with a 1.5 T scanner: A case series in a middle-income country.

OBJECTIVE: The aim of this study was to characterize the capability of detection of the resting state networks (RSNs) with functional magnetic resonance imaging (fMRI) in healthy subjects using a 1.5T scanner in a middle-income country. MATERIALS AND METHODS: Ten subjects underwent a complete blood-oxygen-level dependent imaging (BOLD) acquisition on a 1.5T scanner. For the imaging analysis, we used the spatial independent component analysis (sICA). We designed a computer tool for 1.5 T (or above) scanners for imaging processing. We used it to separate and delineate the different components of the RSNs of the BOLD signal. The sICA was also used to differentiate the RSNs from noise artifact generated by breathing and cardiac cycles. RESULTS: For each subject, 20 independent components (IC) were computed from the sICA (a total of 200 ICs). From these ICs, a spatial pattern consistent with RSNs was identified in 161 (80.5%). From the 161, 131 (65.5%) were fit for study. The networks that were found in all subjects were: the default mode network, the right executive control network, the medial visual network, and the cerebellar network. In 90% of the subjects, the left executive control network and the sensory/motor network were observed. The occipital visual network was present in 80% of the subjects. In 39 (19.5%) of the images, no any neural network was identified. CONCLUSIONS: Reproduction and differentiation of the most representative RSNs was achieved using a 1.5T scanner acquisitions and sICA processing of BOLD imaging in healthy subjects.